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ABSTRACT
This article concerns development and use of patient-
reported outcomes (PROs) in clinical trials to evaluate
medical products. A PRO is any report coming directly from
patients, without interpretation by physicians or others,
about how they function or feel in relation to a health con-
dition and its therapy. PRO instruments are used to measure
these patient reports. PROs provide a unique perspective on
medical therapy, because some effects of a health condition
and its therapy are known only to patients. Properly devel-
oped and evaluated PRO instruments also have the potential
to provide more sensitive and speciﬁc measurements of the
effects of medical therapies, thereby increasing the efﬁciency
of clinical trials that attempt to measure the meaningful
treatment beneﬁts of those therapies. Poorly developed and
evaluated instruments may provide misleading conclusions or
data that cannot be used to support product labeling claims.
We review selected major challenges from Food and Drug
Administration’s perspective in using PRO instruments, mea-
sures, and end points to support treatment beneﬁt claims in
product labeling. These challenges highlight the need for
sponsors to formulate desired labeling claim(s) prospectively,
to acquire and document information needed to support
these claim(s), and to identify existing instruments or develop
new and more appropriate PRO instruments for evaluating
treatment beneﬁt in the deﬁned population in which they will
seek claims.
Keywords: clinical trials, FDA, patient-reported outcomes,
PRO, QOL, statistical analysis.
Why a Guidance on Patient-Reported
Outcomes (PROs)?
Frequently, it is not possible to evaluate effectiveness of
new medical products (which include drugs as well as
medical devices and biological products) without
direct input from patients for whom the product is
intended. Survival or changes in clinical tests may not
be the only outcomes of interest. For example, in
evaluating therapy for community acquired pneumo-
nia, mortality is the critical outcome, and a measure of
patient symptoms would be an important complemen-
tary outcome. In contrast, in evaluating therapies for
osteoarthritis, patient symptoms are of central interest,
and survival is not usually the most relevant outcome,
because osteoarthritis does not directly affect mortal-
ity. In some cases, such as functional dyspepsia,
patients’ perceptions of symptoms (i.e., abdominal
pain) and the symptoms’ impact on functioning are
the only outcomes relevant for evaluating therapies
because no clinical test or physical evidence is
available.
Clinical trials evaluating medical product effective-
ness increasingly incorporate self-reported outcomes
from patients, known in the context of clinical trials as
PROs. These reports help to determine the magnitude
of treatment beneﬁt, that is, improvement in survival
and how patients feel and function as a result of
medical therapy. PROs are a category of outcomes that
one can distinguish from other types of outcomes,
including laboratory measures, clinician ratings, and
caregiver reports.
A PRO is any report coming directly from patients,
without interpretation by physicians or others, about
how they function or feel in relation to a health
condition and its therapy. PRO instruments (e.g.,
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questionnaire items, instructions, and guidelines for
scoring and interpretation) are used to measure these
patient reports.
The term “PRO” is often used to refer to the things
being measured (i.e., concepts and domains (discrete
concepts within a multidomain concept)), the instru-
ment used to measure the concepts, and the actual end
points (i.e., the outcomes as analyzed in a particular
clinical trial). We advise, however, that it is critical to
distinguish the concept and outcome one is attempting
to measure, such as a decrease in pain, from the instru-
ment used to make the measurement, and the end
point used in the statistical analyses. Pain intensity, in
this example, is the concept, decrease in pain intensity
is the outcome, and change over a certain time interval
in pain intensity as measured by a 10-centimeter visual
analog scale (instrument) is the end point used in the
analyses.
Claims are statements or implications of treatment
beneﬁt that appear in any section of a medical prod-
uct’s Food and Drug Administration (FDA)-approved
labeling. Labeling refers to the medical product
description and summary of use, safety, and effective-
ness that the FDA must approve.* When sponsors use
PRO measures to support labeling claims, the FDA
holds them to the same regulatory and scientiﬁc stan-
dards as other measures used in clinical trials. Before
licensing in the United States, a sponsor must provide
evidence that a medical product is safe and effective for
its intended use. For drugs and biological products,
substantial evidence is the standard for making con-
clusions that a drug will have a claimed effect. It
also requires conﬁrmation that adequate and well-
controlled investigations provided the basis for deter-
mining whether there is substantial evidence to
support claims of effectiveness for new drugs. Medical
devices for human use require reasonable assurance of
safety and effectiveness using valid and scientiﬁc evi-
dence. The Federal Food, Drug, and Cosmetic Act (the
Act) speciﬁes these requirements and the Code of
Federal Regulations (CFR) further clariﬁes them.
To inform sponsors, clinicians, and researchers of
FDA’s current thinking on how best to develop and use
PRO measures to support potential claims in product
labeling, the FDA published the draft guidance for
industry “Patient-Reported Outcome Measures: Use in
Medical Product Development to Support Labeling
Claims” [1]. The guidance provides FDA’s current
thinking on the use of PROmeasures for sponsors of all
types of medical products and provides consistency
across three medical-product-speciﬁc Centers within
the FDA, including the Center for Biological Evaluation
and Research (CBER), the Center for Drug Evaluation
and Research (CDER), and the Center for Devices and
Radiological Health (CDRH). After the FDA addresses
public comments, a notice that the ﬁnal guidance has
been released will appear in the Federal Register.
This article reviews selected major challenges in
using PRO instruments, measures, and end point
analyses to support treatment beneﬁt claims in medical
product labeling. Appropriate responses to these chal-
lenges highlight the need for sponsors to formulate
desired labeling claim(s) prospectively, to acquire and
link information needed to support such claim(s)
(including an end point model and conceptual frame-
work for the PRO instrument), and to identify,
develop, or modify appropriate PRO instruments for
evaluating treatment beneﬁt in a deﬁned population.
PROs, Quality of Life, and Health-Related
Quality of Life
Quality of life (QOL) and health-related quality of life
(HRQL) may be considered to be PROs, but the terms
should not be used interchangeably. The term PROs
addresses the source of the report, and not the concept
or content of the report. The organizing term PRO
would never be a claim, i.e., a label would not say
Product x improves PROs. A label claim requires that
the concept or the “thing” being measured is deﬁned,
for example, pain intensity. The draft FDA guidance
describes HRQL as a multidomain concept that repre-
sents the patient’s overall perception of the impact of
an illness and its treatment. HRQL measures capture,
at a minimum, physical, psychological (including emo-
tional and cognitive), and social functioning.
Improvement in HRQL is a highly sought-after
claim by medical product manufacturers. The draft
guidance clearly states that HRQL should not be
equated with QOL which is described as a general
concept that implies an evaluation of the impact of all
*The term medical product includes drugs and biological prod-
ucts as well as medical devices. Labeling refers to the medical
product description and summary of use safety, and effectiveness
that must be approved by the FDA. See 21 CFR 201.56 and
201.57 for regulations pertaining to prescription drug and bio-
logical product labeling. For medical device labeling, see 21 CFR
801. For drugs and biological products, section 505(d) of the Act
establishes substantial evidence as the evidence standard for
making conclusions that a drug will have a claimed effect and
states that reports of adequate and well-controlled investigations
provide the basis for determining whether there is substantial
evidence to support claims of effectiveness for new drugs. See 21
CFR 314.216 for a description of the characteristics of an
adequate and well-controlled investigation. Part of these regula-
tions is the requirement for well-deﬁned and reliable outcome
measures (21 CFR 314.126.(6)). See the guidance for industry
Providing Clinical Evidence of Effectiveness for Human Drug
and Biological Products for considerations concerning the quan-
tity of evidence necessary to meet the substantial evidence
standard. (http://www.fda.gov/cder/guidance/1397fnl.pdf) For
medical devices, the Medical Device Amendments of 1976 to the
Act established reasonable assurance of safety and effectiveness
of medical devices intended for human use. See 21 CFR 860.7 for
the types of valid scientiﬁc evidence used in the determination of
reasonable assurance of safety and effectiveness of a medical
device.
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aspects of life on general well-being. QOL is affected
not only by health status but also by other valued
aspects of human existence such as a safe environment,
adequate housing, guaranteed income and freedom.
Therefore, QOL is not an appropriate outcome for
evaluating a medical product. HRQL, by contrast, can
represent a summation of how patients feel or function
as a result of therapy. Adequacy of an HRQL instru-
ment depends on its ability to measure concepts that
are relevant to the medical condition, including the
important positive and negative concerns of patients
undergoing therapy. HRQL end points, like all other
end points, must be indicators of clear and interpret-
able treatment beneﬁt or harms in clinical trials.
Begin with the End in Mind
Wheel and Spokes Diagram
The development, modiﬁcation, and validation of a
PRO instrument usually occur in a nonlinear fashion
with a varying sequence of events, simultaneous
process, or iterations. The FDA draft guidance sum-
marized this process in four major iterative steps illus-
trated in a wheel and spokes diagram and described
the important considerations for each step. Figure 1
includes ﬁve major steps that we believe are a better
reﬂection of the actual developmental process. When
contemplating the use of a PRO instrument in a clini-
cal trial, all ﬁve steps apply regardless of whether
sponsors use an existing instrument, modify an exist-
ing instrument, or develop a new instrument. The
purpose of the wheel and spokes diagram is to orga-
nize the development process and provide the path by
which the PRO can lead to a claim, as shown in the
hub of the diagram.
The draft FDA guidance emphasizes the need for
documentation of PRO instrument development
(including modiﬁcation), assessment of measurement
properties, implementation, analysis, and interpreta-
tion to support proposed labeling claims. Other
articles in this volume also address these issues. Table 1
outlines major types of documentation recommended
for PRO instruments at each stage. The FDA has not
speciﬁed an exact format for submission of this docu-
mentation, but the elements of documentation are
identiﬁed to provide sufﬁcient information for FDA
review of PRO instruments intended to support
product development.
The Importance of Targeted Claims
FDA advises sponsors wishing to use PROs to ﬁrst
identify the claims they seek in the product labeling.
Success in obtaining a labeling claim based on a PRO
measurement depends on alignment of product devel-
opment, PRO instrument choice or development,
application, analysis and interpretation in the context
of otherwise adequate and well-controlled clinical
trials. To help specify potential PRO-based claims for
drugs, sponsors may use the Target Product Proﬁle
(TPP), a summary of the drug development program
described in the context of prescribing information
goals [2]. A well-developed TPP can facilitate and
improve communication concerning labeling goals and
PRO development and use in clinical trials. The TPP
embodies the notion of “beginning drug development
with the goal in mind.” Early in product development,
as suggested in Fig. 1, sponsors should link targeted
claims to hypothesized concepts. To be used effectively,
a sponsor updates a TPP before each discussion with
FDA throughout all phases of the Investigational New
Figure 1 PRO instrument development and
application in FDA. FDA, Food and DrugAdmin-
istration; PRO, patient-reported outcome.
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Table 1 Recommended Documentation for PRO Instruments Used in Clinical Trials*
Targeted or potential claims
1. List all targeted or potential treatment beneﬁt claims for the medical product or device (Target Product Proﬁle)
2. Identify potential claims to be supported by PRO instruments and end points
3. Link each targeted PRO claim to a hypothesized concept to be measured by PRO instrument(s).
Describe intended population (diagnosis, age, gender, or other characteristics)
Describe intended rationale and PRO instrument characteristics. Hypothesized PRO conceptual framework
1. For each PRO instrument comprised of single items or more than a single item, provide a diagram of concepts measured by each item, domain, or
overall score, if applicable.
2. Provide summary of all literature reviews
3. Provide documentation on development of conceptual framework using literature review and expert input.
Model of hypothesized relationships among end points (end point model)
1. List all measures (PRO and non-PRO) that may be used as study end points in the clinical trial(s) to support claims. (This may include
physiologic\lab\physical, caregiver, clinician-reported or patient-reported measures.)
2. Place PROs within this preliminary end point model\hierarchy
3. Describe hypothesized relationships among these measures.
Adjust conceptual framework and document instrument development, item generation, and content validity
1. Chronology of all item development activities
2. Protocols for qualitative interviews and focus groups, cognitive debrieﬁng interviews and any other research used to identify concepts, generate
items, or revise an existing instrument, including training of interviewers
3. Development of response options, modes of administration and scoring
4. Size, characteristics, location, and (if requested) transcript of each qualitative interview and focus group
5. Documentation on how saturation was achieved (i.e., no new information was obtained from additional qualitative interviews or focus groups)
6. Description of any pilot test, including cognitive interviewing transcripts (if requested)
7.Versions of the instrument at various milestones of development
8. Item tracking table that list the source of each item in the ﬁnal instrument, and how it changed during development
9.A summary statement of qualitative research in support of content validity of the PRO instrument, i.e., how does the qualitative research listed
above support the conclusion that the PRO instrument measures the concept(s) that it purports to measure and that are reﬂected in the
proposed claims.
Conﬁrmation of conceptual framework and assessment of PRO measurement properties
1. Protocols for PRO instrument development (design, methods, analysis plan)
2. Documentation of psychometric testing for each domain or summary score proposed as support for claims
a. Conﬁrmation of conceptual framework (concepts, domains, scores)
b. Reliability
i. Cronbach’s alpha
ii. Test–retest reliability
c. Construct validity
i. Convergent validity
ii. Discriminant validity
iii. Known-groups validity
d.Ability to detect change
3. Descriptive and statistical analysis ﬁndings from each study
4. Estimate of patient burden
5. Instrument user manual that includes
a. Procedures for PRO administration in its ﬁnal format
b. Scoring
c. Final version of instrument in all alternate forms
Trial protocol-related documentation: in addition to usual protocol concerns*
1.The ﬁnal version of the instrument planned for use in clinical trials.
2. Instrument administration procedures, training and instructions for patients and study personnel
3. Data collection, data storage, and data handling/transmission procedures, including ePROs
4. PROs in Statistical analysis plan
a. Proposed Responder deﬁnition
b. How between-group differences will be described (e.g., cumulative distribution function)
c. Plans for conﬁrmation of PRO instrument measurement properties within the clinical trial
d. Plans to avoid missing data at both the instrument and patient levels
e. Plans for multiple end point testing
Modiﬁcations of existing or new instruments
1. For language translations and cultural adaptation processes, include:
a. Description of the expertise of the translators
b. Description of procedures used (forward, back, reconciliation, harmonization, assessment of measurement properties)
c. Description of patient testing
d. Results of translation/adaptation including clear description of all translation issues and how they were resolved
2. For content, wording, format, or mode of administration changes, describe results from studies conducted to evaluate modiﬁcation, or rationale for
not conducting studies
3. For use in a new indication or new population, document instrument development and assessment of measurement properties as described above.
Bibliography
1. Provide listing and copies of all relevant published and unpublished documents.
*Department of Health and Human Services, Food and DrugAdministration,Center for Drug Evaluation and Research. (1988) Guideline for the format and content of the clinical
and statistical sections of an application. See Appendix C, in particular. http://www.fda.gov/cder/guidance/statnda.pdf.
PRO, patient-reported outcome.
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Drug application process. As sponsors complete clini-
cal trials, an updated TPP may serve as the basis for an
ongoing dialogue on evolving goals. Although the
approval process for medical devices does not use the
TPP per se, the process of beginning with the desired
claims and designing the studies to assess these claims
is the same.
Table 2 illustrates the matching of desired product
claims ﬁrst to PRO concepts and then to PRO instru-
ments. In this hypothesized example, the claim sug-
gests that the medical product reduces problems with
swallowing and speaking to others and improves daily
activities. End point analyses would determine statis-
tical signiﬁcance and clinical meaningfulness of these
changes. The concepts are clearly identiﬁed and the
instruments are listed that operationalize the concepts
and represent possible claims of treatment beneﬁt. The
actual measurement strategy relating to these claims
and concepts could employ a single instrument
with three domains that are speciﬁc to the intended
measurement concepts. Alternatively, sponsors could
use three separate instruments. Regardless of the mea-
surement strategy, sponsors should provide copies of
the actual instrument(s) speciﬁed and documentation
supporting the adequacy of the instrument(s) to FDA
reviewers.
Hypothesized Conceptual Framework
The adequacy of a proposed instrument to support a
claim depends on the conceptual framework of the
instrument, i.e., a diagram of the relationships between
the questionnaire items in a PRO instrument and the
concepts measured by the instrument and represented
as scores [3]. An instrument may create a single score,
thereby measuring a single concept, or it may be devel-
oped with multiple domain scores each represented by
a concept within a more general concept of measure-
ment. Table 3 illustrates a simple conceptual frame-
work for a PRO instrument using three PRO concepts
to assess outcomes of treatment for head and neck
cancer as an example, namely, swallowing, speaking,
and basic activities of daily living.
With a clearly stated target claim, identiﬁed con-
cepts, and a hypothesized conceptual framework for
the PRO instrument, the sponsor can review the scien-
tiﬁc literature to determine whether an existing PRO
instrument is adequate or if one needs a new or modi-
ﬁed PRO instrument to secure the desired claim. The
conceptual framework evolves and is adjusted after
patient input and assessment of measurement proper-
ties, as shown in Fig. 1. The conﬁrmed conceptual
model is sometimes known in the ﬁeld of outcomes
measurement as the measurement model, including
how items, domains, and total scores are derived.
Preliminary End Point Model
Early in product development, sponsors are encour-
aged to identify all measurement concepts—PRO and
non-PRO—that may be appropriate for end point deﬁ-
nition in clinical trials designed to support claims. To
facilitate communication with the FDA, the sponsor
may want to prepare a preliminary endpoint model
(i.e., a plan for end point measurement) that speciﬁes
the hierarchy and hypothesized relationships among
all treatment beneﬁt end points intended to support
claims. At a minimum, an end point model describes
measurable concepts of a speciﬁc disease state, includ-
ing the spectrum of both prominent symptoms and
expected clinical course; additional treatment-speciﬁc
concepts relevant to the patient population are incor-
porated into the model.
PRO end points are placed within this model
within the hierarchy of all end points. In this way
sponsors can lay out their hypothesized relationships
among all measures—including PRO and non-PRO
measurements—that could serve as end points in terms
of overall goals of therapy. Articulation of an end point
Table 2 Linking PRO concepts to claims
Desired claim PRO concept PRO instrument(s)
Product X reduces problems with 
swallowing and speaking to others 
and improves daily activities 
Swallowing 
Speaking to others 
Daily activities 
Swallowing diary and retrospective report
Conversation diary
Daily activities diary
PRO, patient-reported outcome.
Table 3 Three concepts of head and neck cancer: simple con-
ceptual framework
Items PRO concept
Difﬁculty in  Swallowing
• Swallowing saliva
• Swallowing liquids
• Swallowing solid foods
Difﬁculty in  Speaking
• Speaking loud enough
• Being understood by others
Difﬁculty in  Basic activities of
• Eating daily living
• Dressing
• Bathing
• Toileting (using the
bathroom)
• Transferring (moving back and
forth from bed to chair)
• Remaining continent
PRO, patient-reported outcome.
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model ties together disease natural history, treatment
goals, and the instrument(s) intended to demonstrate
treatment beneﬁt. This preliminary end point model
also informs the development of the clinical study
protocol(s) and its ﬁnal depiction, after adjustment
through the different phases of clinical research, is
reﬂected in the Statistical Analysis Plan for registration
or phase III clinical trials.
FDA, sponsors, and researchers always use an end
point model, although they do not always explicitly
state their thinking as such. End point deﬁnition is a
basic process used in clinical trials. Formal articulation
of the ﬁnal model is not required at this point. The
preliminary end point model provides a context to
show how multiple end points ﬁt together to support
the primary hypothesis being addressed in a clinical
study supporting a product approval.
Table 4 provides a hypothetical end point model for
the head and neck cancer example. Clinical end points
would include overall survival and progression-free
survival as determined via radiographic and clinical
assessment, which if signiﬁcant statistically and inter-
preted as a medically important, would be sufﬁcient
for a claim. If these two survival end points showed a
treatment beneﬁt, a physician-reported performance
status assessment, as often included in cancer clinical
trials, would be acceptable as part of the analysis. The
three PRO instruments are subsequently listed in order
of importance as complementary end points that may
result in a claim.
End point models should be linked to natural
history for the condition and what is known about the
relationship of concepts and end points. A clear end
point model specifying outcomes that will be the basis
for claims is important for all end points but is par-
ticularly helpful in elucidating the importance of PRO
measures in the end point hierarchy that are intended
for labeling claims.
FDA Review of Instrument Development
Food and Drug Administration determines adequacy
of a PRO instrument based on review of the instru-
ment’s development, modiﬁcation, adaptation, assess-
ment of measurement properties, implementation in
clinical trials, and interpretation of the PRO end points
in evaluating treatment beneﬁt. All aspects of use of a
PRO instrument are evaluated in relation to the
intended labeling claim. This allows FDA to determine
whether the instrument provides a valid and reliable
measure of the concept(s) implied or stated in labeling
claims and provides sufﬁcient evidence to support
claims. This evidence, however, does not mean that
sponsors must demonstrate the validity of a PRO
measure “beyond a reasonable doubt.” In any ﬁeld of
science, there is always a degree of uncertainty related
to results of an experiment, but the goal is to minimize
uncertainty to a degree that is acceptable for public
health.
The draft PRO guidance does not set precise criteria
for the level of evidence sufﬁcient to demonstrate that
a PRO instrument is adequate to measure a particular
medical product claim. This allows FDA and sponsors
ﬂexibility when developing and reviewing an instru-
ment and allows accommodations for changes and
Table 4 Hypothetical end point model for head and neck cancer
Progression concept End point
Hierarchy for consideration of
drug approval
1 = By itself sufﬁcient*
2 = If Overall Survival and
Progression-Free Survival not in
wrong direction, acceptable as a
component of a time-to-event progression
metric with swallowing, speaking,
and activities
Longer life Overall Survival (OS)

1
Better life—absence of disease progression Progression-free survival (PFS) as determined
via radiographic and clinical assessment

1
Better life—clinician-reported function Clinician-rated performance status score

2
Better life—patient-reported function Swallowing diary score

2
Better life—patient-reported symptoms Conversation diary score

2
Better life—patient-reported function Daily activities measure score 2
*If of sufﬁcient magnitude in the context of an acceptable risk-beneﬁt ratio
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advances in the science of patient-reported measure-
ments. Sponsors should be aware, however, that prior
acceptance of an existing PRO instrument as an
adequate measure of a concept for nonregulatory or
regulatory purposes (including by FDA) does not
ensure that the instrument is adequate by current stan-
dards to support FDA-approved medical product
labeling claims. Furthermore “expert opinion” sup-
porting “face validity” of an existing PRO instrument
or its development does not constitute sufﬁcient evi-
dence. Aspects of instrument selection and design of
the measurement strategy are addressed in Snyder
et al. [4] and Turner et al. [5].
Evaluating Content Validity and Adjusted
Conceptual Framework
The essential ﬁrst step in developing a PRO instrument
is ascertaining that the measured concepts cover what
patients consider the most important outcomes of the
condition and its therapy. This is often called estab-
lishing the content validity of the instrument. Unfortu-
nately, researchers often give insufﬁcient attention to
this step and concentrate more attention on establish-
ing other measurement properties.
It is important that one take into account patients’
perspectives when developing PROs, as the whole
point of the endeavor is to measure patients’ experi-
ences. The measurement properties of the instrument
have little meaning if one is not measuring something
important to patients. The qualitative interview strat-
egy, description of qualitative interviews and focus
groups, transcripts, coding procedures, and justiﬁca-
tion for each version of the developing instrument
support the adequacy of the development process.
Qualitative methods include both item generation
and cognitive. This documentation provides a record
for the assessment of each version of the PRO instru-
ment used throughout development so that FDA
reviewers can track evolution of a PRO instrument
from its inception to the version(s) used in trials. Also
valuable for content validity review is a listing of all
items with all changes made to each item as each
instrument version is developed, the rationale for deci-
sions to drop, retain, or modify items, and a record of
items added or dropped. All changes in response
options and proposed recall periods should also be
documented.
Table 5 illustrates how to track the history of item
development in an instrument, using swallowing as an
example. The long list of items elicited during qualita-
tive interviews and focus groups or from existing
instruments provides the basis for the table. Each item
is tracked through the different stages of development
(item generation and cognitive interviews). The ﬁnal
column indicates whether each item is dropped or
retained for assessment of measurement properties
and, eventually, clinical trial analyses and gives the
reasons or evidentiary support for each decision.
Conﬁrming Conceptual Framework and
Assessing Measurement Properties of a
PRO Instrument
FDA reviews measurement properties of the version of
a PRO instrument sponsors used in clinical trials to
conﬁrm the conceptual framework such that scores
generated from the instrument are reliable, valid, and
able to detect change. Measurement properties of such
instruments are a function of many factors, including
instrument formats and mode of administration, popu-
lation studied, and properties of the scoring system [6].
Sponsors should base documentation of measurement
properties on the PRO instrument version they plan to
use in trials. In evaluating an instrument, sponsors
should use relevant study populations and proposed
scoring procedures that correspond to those used for
evaluation of treatment outcomes with the PRO
instrument in the clinical trial. Frost et al. in this
volume addresses issues of reliability and validity [7].
Table 5 Simple item tracking matrix with swallowing measure as example
Long list of items Item source Final decision
How much difﬁculty do you
have swallowing?
Qualitative interviews/focus groups Dropped—high frequency, low severity, too vague in meaning, did not
discriminate between severity levels. Patients reported difﬁculty in
averaging over time in retrospective report
How much difﬁculty do you
have swallowing liquids?
Qualitative interviews/focus groups Retained—high frequency of report, high importance to patients,
worked well in cognitive interviews and discriminated between
severity levels. 24-h diary recall preferred by patients
How much difﬁculty do you
have swallowing soft foods?
Qualitative interviews/focus groups Dropped—highly correlated with swallowing solid foods and will be
covered by that item
How much difﬁculty do you
have swallowing solid foods?
Existing instrument—head and neck
cancer swallowing diary
Retained—worked well in cognitive interviews and discriminated
between severity levels
24-h recall period preferred by patients
How often do you need to spit? Qualitative interviews/focus groups Dropped—highly correlated with swallowing saliva—related to other
conditions
How much difﬁculty do you
have swallowing your saliva?
Qualitative interviews/focus groups Retained—worked well in cognitive interviews—high importance to
patients
24-h recall period preferred by patients
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Reliability
Some assessment of the extent to which a PRO instru-
ment yields consistent, reproducible estimates is
important. Test–retest reliability conﬁrms that the
same assessment collected at multiple time points using
identical methods produces the same results if the
patient’s condition has not changed. If a sponsor mea-
sures a concept using multiple highly correlated PRO
items summarized into a single score, the sponsor can
measure internal consistency reliability of these items
(generally measured using Cronbach’s coefﬁcient alpha
[8]) to determine agreement among responses to dif-
ferent questions. If a single score is used to summarize
domain or subconcept measures (e.g., severity of
symptoms of a disease; HRQL domain scores), inter-
nal consistency of the subconcept measures is not an
appropriate measure of reliability [9].
Evidence of internal consistency reliability is not
sufﬁcient to assure that scores are stable over time, that
scores change with or without treatment, or that scores
are valid measures of a concept [10]. Sponsors should
include in documentation of reliability testing a
description of populations assessed, rationale for the
time period used to evaluate the instrument under
stable conditions, and if applicable, how sponsors
used internal consistency to evaluate domain and total
scores.
Validity
Documenting validity of a PRO instrument, i.e., the
extent to which the test measures what it purports to
measure, involves demonstrating that the sponsor has
tested the instrument in the population of interest
(patients with similar disease severity, condition, lan-
guage or culture, and demographic characteristics) and
in a context roughly similar to that in which the
sponsor will eventually perform clinical trials. As
stated above, at a minimum, sponsors should demon-
strate content validity of a PRO instrument based on
studies showing that the PRO instrument captures the
issues that patients in the target population indicate
are important about the concept reﬂected in the claims.
For example, a PRO intended to assess fatigue may
lack content validity if it measures only affective mani-
festations of fatigue without considering behavioral or
physical components.
Food and Drug Administration also looks for other
empiric evidence of PRO instrument adequacy as a
measure of the concepts associated with product
claims, including the following:
• conﬁrmation of the conceptual framework for the
PRO, items, domains, and total score if applicable
and how obtained;
• correlation of PRO data with other important end
points as hypothesized in the end point model;
• ability to discriminate among patients that differ
on important characteristics, e.g., disease severity;
• comparable results among different language ver-
sions or alternative modes of administration for
the PRO instrument.
A single PRO instrument used in one setting or
population may not be valid in another population or
setting, therefore there is no universal “validation” of
a PRO instrument. Consequently, measurement prop-
erties should again be conﬁrmed in each clinical trial
that will be used to support claims.
Ability to Detect Change
When one expects a concept to change with therapy,
values for the PRO instrument measuring that concept
also should change with effective treatment. If they do
not, one should question validity of the PRO instru-
ment. A small, blinded study completed before Phase
III may be sufﬁcient to document that scores change
based on a PRO when the patient’s status on the
concept of interest changes, even if the study is not
powered to demonstrate a statistically reliable treat-
ment beneﬁt. Ability to detect change usually is
reﬂected by effect size statistics in which higher values
indicate larger effect sizes. Larger effect sizes usually
imply that a smaller sample size will sufﬁce to evaluate
therapeutic beneﬁt using a PRO instrument.
Data Analyses and Interpretation of PRO End
Points in a Clinical Trial
Interpretability means the degree to which one can
assign easily understood meaning to an instrument’s
quantitative score in a particular application. Interpre-
tation is separated in Fig. 1 as it may vary with the
clinical trial population and protocol and thus is not
considered a property of the PRO instrument per se
even though accumulated evidence with individual
measures may suggest a particular meaning of a score
change.
One of the major concerns of clinicians regarding
use of PRO instruments is uncertainty in translating a
score into a meaningful treatment beneﬁt for patients.
When clinical trials use changes in PRO instrument
scores as study end points, sponsors should provide
interpretation of the magnitude of changes in PRO
scores that patients can perceive and that patients con-
sider beneﬁcial.
The degree of change that patients would consider a
meaningful therapeutic beneﬁt may vary depending on
patients’ medical conditions, disease severity, or stage
of disease. The magnitude of change important to
patients may be different when measuring improve-
ment compared to measuring worsening. FDA re-
viewers consider these factors when reviewing the
documentation to support recommended guides for
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interpreting study results based on a PRO end point
measure. We discuss approaches to interpretation of
PRO scores below in the section on analysis and inter-
pretation. Sloan et al. [11] and Revicki et al. [12] in
this volume also address these issues.
Modifying an Instrument
Any change in a PRO instrument can potentially affect
its measurement properties. One can inﬂuence answers
to self-administered questionnaires by changes in
wording of items or response options, changes in item
order, addition or elimination of items, changes in
recall period, changes in mode of administration, and
by changes in visual presentation of items and
responses. Modifying PRO instruments may affect
distribution of item responses, leading to changes in
domain and overall scores. Survey research literature
contains examples of these effects in many situations
[13,14].
What Modiﬁcations are Important to Study
An important point of discussion with the FDA is the
degree of modiﬁcation that may occur to an existing
instrument before it is considered a new instrument, in
turn triggering the need for further investigation of
measurement properties in the population of interest.
Not all modiﬁcations necessitate testing the new
instrument version in a randomized trial or even a
large study of measurement properties. Yet when an
instrument is modiﬁed, sponsors should consider addi-
tional studies for conﬁrmation of the modiﬁed instru-
ment’s measurement properties.
The extent of additional studies depends on the
nature of modiﬁcations made to the instrument [15].
Sponsors may use small methodological studies to
compare results from the original and revised instru-
ments. Cognitive interviewing is a qualitative method
for assessing respondents’ interpretation of a question
or item. For example, one can use “think aloud” tech-
niques such as ask respondents to describe how they
arrived at responses to illuminate thought processes
involved in answering questions. A small study, for
example, may be adequate to assess results of changing
presentation of a response scale from a vertical to
horizontal axis. Sponsors would need to perform a
larger study to investigate effects of adding new items
or deleting entire domains or changing recall periods.
Using a PRO instrument in an entirely new popu-
lation of patients may affect an instrument’s measure-
ment properties, for example, using instruments
developed in adults with children or adolescents or in
patients with various degrees of severity of a disease.
If the sponsor plans to use a PRO instrument in an
entirely new population of patients, the sponsor may
need to perform additional qualitative studies to
conﬁrm that items and response options are relevant
and understandable to the new population and to iden-
tify any new issues of importance to these patients.
FDA recommends an additional study of measurement
properties or investigation of measurement properties
in a randomized study to ascertain measurement prop-
erties in the new population. Such investigation may
minimize the risk that an instrument will not perform
adequately in a study used to support labeling or
promotion.
Finally, an instrument that a sponsor translates for
use in a new language and culture is considered a
modiﬁed instrument. Randomized studies to test each
culturally adapted version of an instrument may not be
possible given that sponsors use PRO instruments in
many different languages and cultures. It may be pos-
sible, however, to verify basic measurement properties,
such as distribution of responses, internal consistency,
test-retest reliability, and validity in at least a few dif-
ferent languages used in the largest populations to be
studies in the clinical trials. Alternatively, in a pivotal
study supporting a label claim, sponsors may evaluate
basic measurement characteristics such as distribution
of responses, means, standard deviations, etc. for dif-
ferent language groups, when sufﬁciently large.
Issues in Study Planning,Analysis,
and Interpretation
Design and analysis considerations for clinical trials
that use PRO end points as the basis for labeling claims
are the same as for trials using any other type of
clinical end point. Principles of appropriate study
design and analysis are well described in other FDA
guidance [16]. In particular, sponsors should identify
and specify a priori the end points of interest that
characterize the desired claims. Trial end points should
be consistent with other study objectives and must not
be arbitrary or chosen retrospectively as part of an
exploratory effort, e.g., data dredging after collection
of data on numerous unrelated end points with the
hope that a few will show an effect of treatment. The
trial protocol should prospectively deﬁne the place of a
PRO instrument in terms of the hypothesis tested in
the trial. For instance, end points measured with PRO
instruments can be sole end points, part of composite
end points, or serially tested end points. As with any
end points studied in a clinical trial, those without
reproducibility or lacking an adequate ability to detect
change will be detrimental to the success of the trial
and to interpretation of results.
In the protocol, sponsors should consider and plan
for the risk of false positive results by designating
criteria for concluding a positive treatment beneﬁt and
how many ways treatment beneﬁt might be achieved,
especially if end-point-speciﬁc claims are desired. This
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requirement is part of specifying the hypothesis to be
tested in any trial.
Simultaneous statistical testing of multiple study
end points can increase the chances of a false positive
conclusion, by inﬂating the Type 1 error rate as a result
of allowing so many ways to conclude that a treatment
beneﬁt on one or more end points exists. Prospective
articulation of the trial’s statistical analysis plan
addresses this risk and minimizes the likelihood of
false positive conclusions. Acceptable statistical
approaches include use of “closed testing” procedures,
gatekeeper/ﬁxed-sequence methods, or assignment of
allowable type 1 error (alpha, the prespeciﬁed false
positive rate) to different families of end points. If there
is a clinically relevant order or a hierarchy to PRO end
points (i.e., if some PRO end points are more impor-
tant to patients than others), then a gate-keeper/ﬁxed-
sequence approach may be most appropriate. None of
these techniques are new or speciﬁc to PROs; pub-
lished guidance describes these methods and their
applications [16].
The study planning process should also include a
consideration of issues related to missing data [17].
Patients who fail to complete a clinical trial or who
withdraw from assigned therapy before trial comple-
tion will not provide outcome data or measures of
treatment response. This concern is important in every
clinical trial. Missing data because patients withdraw
early from a trial is particularly problematic when
measuring outcomes using PROs, because missing
outcome or response data may be a predictor of an
individual’s satisfaction with the treatment while in the
trial. For example, patients may drop out of a trial
because they consider the therapy ineffective, because
of adverse effects, or because of dissatisfaction with
some other aspect of the clinical trial experience. With-
drawal in studies involving severely ill patients may be
related to inability to provide data or visit the clinical
center. Quantity of missing data, time points when
data were missed, and treatment group(s) affected may
each adversely affect ability to interpret trial results. Of
particular concern is how likely it is that the analysis of
data from individuals who complete the trial will yield
an accurate and unbiased estimate of the real treat-
ment effect of the therapy. In their protocols, investi-
gators must plan for an analysis of all data on all
patients randomized, i.e., intent-to-treat analysis, even
while recognizing that incomplete patient response
proﬁles may exist for some subset of patients.
Trial results are more likely to be biased when the
amount of missing data is substantial. Ideally investi-
gators will have devised a plan for obtaining data on
each patient at the time of withdrawal to determine
reasons for withdrawal and if possible at another time
subsequent to withdrawal from assigned treatment
exposure but before planned trial completion. This
information is often useful with regard to understand-
ing treatment response and perhaps can be taken into
account in the analysis. Thus the statistical analysis
plan should provide approaches for analyses of
missing data (e.g., missing items within domains,
missing entire domains, or missing entire measure-
ments) when evaluating treatment efﬁcacy.
Researchers generally use a PRO instrument to
ascertain a patient’s status at baseline or study entry
and at subsequent time points during the clinical trial.
A patient’s response to treatment is measured by
changes in PRO scores from baseline to the end of that
patient’s assessments during the trial. All clinical trials
evaluate the effect of medical interventions in groups
of patients who receive a medical intervention com-
pared with the effect in patients who receive a control
intervention (either active or placebo, or both).
Two main conceptual approaches exist to clinical
trial analyses of patient response to treatment as mea-
sured by PROs: 1) comparison of the average change
from baseline across all patients in treatment and
control groups according to some between group cri-
teria, also called the minimum important difference
(MID); and 2) comparison of the proportion of
patients in the treatment and control groups who meet
a prespeciﬁed criterion for response, also called a
“responder criterion.” Each approach requires plan-
ning to support interpretation of study results.
Analysis of Mean Change
Change for a treatment group averaged over all
patients in a treatment group relative to the average
change in a control group (active, placebo, or both)
may be viewed as overall treatment effect size. The
treatment effect size is an estimate of the true unknown
treatment effect that the trial is intended to measure.
Within a clinical study, researchers may propose a
theoretical treatment effect size they consider to be
important or clinically meaningful. This theoretical
treatment effect size is the MID between or among
treatment and control group means. The MID is thus
presumed to represent a meaningful treatment beneﬁt
when the treatment and control groups each are con-
sidered as a group.
Point estimates of the difference in means between
two groups, however, may mask important changes for
individual patients or types of patients in each group.
This problem arises because some types of patients
within each group will tend to respond better or worse
than others, often depending on baseline values of the
end point. For example, groups of patients at different
levels of severity at baseline may show higher or lower
changes as measured by the PRO instrument than
patients at other baseline starting points. All patients,
regardless of either their baseline status or their change
from baseline, contribute to a group mean estimate of
response to treatment; for that reason the point esti-
mate of the group mean change can be large or small
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depending on the distribution of individual PRO
change scores within the group. Overall results may be
driven by extremes of patient distribution at baseline
or following treatment. The MID will thus not reveal
whether some groups within the trial obtain a large
beneﬁt while other groups do not beneﬁt at all.
Analysis of the cumulative distribution of patients’
response to the experimental treatment within each
group compared to responses of the control groups can
help in evaluating the consistency of effects across the
entire distribution. This distribution curve will reveal
the extent to which overall results are driven by outli-
ers who improve or worsen more than others. A cumu-
lative distribution curve provides information on what
type of responses contributed to the mean group
response and provides more useful data than a simple
point estimate of the difference between group mean
changes.
Figure 2 provides an example of a cumulative dis-
tribution curve. FDA and sponsors have used this tech-
nique in product labeling to display treatment effect
data [18–21]. The ﬁgure shows that change from base-
line ranges from a negative 6 to a positive 6 with
positive changes indicating improvement in the PRO.
Fig. 2 shows that the two drugs (A and B) are clearly
distinguished from placebo beginning at the no change
point to 6 points above. Different cumulative distribu-
tion curves can be anticipated depending on the distri-
bution of the effect as measured by the end point and
its variance.
Results based on the MID may be more difﬁcult for
clinicians to interpret because the MID results are pre-
sented in terms of the score itself, rather than in terms
of the proportion of patients who beneﬁt from treat-
ment. One may not be able to extrapolate differences
among treatment groups to the magnitude of change in
score that an individual patient may perceive as ben-
eﬁcial. This makes the determination of a clinically
meaningful MID threshold challenging. For these
reasons, FDA encourages sponsors to consider using
cumulative distribution curves rather than MID
criteria to demonstrate effect of treatment on PRO end
points.
If sponsors do choose to use MID criteria in addi-
tion to the cumulative distribution to assess treatment
beneﬁt, the measured difference between the mean
scores of each treatment group, usually including its
entire conﬁdence interval, should exceed the chosen
MID. Fig. 3 illustrates that a difference in point esti-
mates of approximately 10 points is the MID. Only the
result at the far right of the ﬁgure in which the conﬁ-
dence interval exceeds the MID would constitute a
“win.” Nevertheless, the requirement that the conﬁ-
dence interval exceed the MID can be difﬁcult to
attain, because it entails modifying the null hypothesis
from “is there a treatment effect greater than zero?” to
“is there a treatment effect greater than the MID?”
Achieving this objective may require a larger sample
size than would otherwise be necessary or feasible in a
clinical trial.
For these reasons, most commonly, only the point
estimate needs to exceed the MID, and the lower
bound of the conﬁdence interval only needs to exclude
no difference at all between groups. Therefore, most
end point values are not judged against the require-
ment that the conﬁdence interval exceed the MID.
Regardless of the difﬁculty in interpreting the MID,
estimates of the size of the treatment effect on each end
point studied in a clinical trial is usually taken into
account in beneﬁt-risk judgments.
Analysis of Responders
An alternative way to analyze patient response to
treatment as measured by PROs is to focus on within-
individual patient changes in each treatment group and
determine the proportion of patients who respond
adequately to treatment. To compare the proportion of
responders between treatment groups, one must estab-
lish responder criteria at the individual patient level
that identiﬁes within patient PRO changes known or
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shown to be of perceptible importance and meaningful
to patients. The responder criteria are used to measure
the proportion or cumulative proportion of patients
in each group who meet these predeﬁned criteria of
successful treatment response, e.g., the proportion of
patients in the acetaminophen group who achieved a
score of 2 or less on a 0–10 pain intensity scale com-
pared to the proportion of patients in the opiate anal-
gesic group meeting the same criteria.
In analyzing the proportions of responders, investi-
gators must still interpret the degree of change that
represents an important difference or clinical meaning-
ful difference between the proportions of responders in
each treatment group. Just as for analysis of means,
examination of the cumulative distribution curve can
be useful to interpret study results in an analysis of
proportions.
A major difﬁculty with using a responder analysis is
that sponsors must deﬁne criteria for an individual
responder before starting the trial. This step may
require some preliminary study to determine an appro-
priate value. Methodologies have been proposed to
evaluate and deﬁne the minimum change that individu-
als perceive as being important and meaningful to
them as part of the PRO instrument development
process. However, appropriate standards have
yet to be developed for responder deﬁnitions [11].
More research is needed in methods for identifying
and applying responder criteria.
Conclusion:Toward Better Measurement of All
Clinical Trial End Points
PROs and Clinical Trial End Points
Measurement principles stated in FDA’s draft PRO
guidance are an extension of principles that apply to
all end point measures whether or not a PRO is
involved. As stated above, a PRO instrument is but one
way to deﬁne and measure end points for clinical trials.
The draft guidance describes measurement properties
of end points generally, with application to PROs in
particular. All end points, however, should meet
similar criteria. We hope that discussions regarding
design of trials using PROs will shed light on issues
regarding measuring other (e.g., laboratory, clinician-
reported, caregiver-reported) end points as well.
The draft guidance provides recommendations, not
requirements. No guidance can encompass all situa-
tions that may arise when designing clinical trials for a
wide variety of disease areas. As science advances and
new tools become available, FDA will continue to seek
to consider new methods for demonstrating overall
treatment beneﬁt. Equally important, depending on
the magnitude of effect observed, the Agency has con-
siderable ﬂexibility in allowing use of PRO instru-
ments that may not fulﬁlll all of the principles
articulated above.
PRO instruments may allow additional measure-
ments of ways in which therapies may beneﬁt or harm
patients. For instance, a new therapy may have a
similar survival advantage relative to existing thera-
pies, but it may also provide other beneﬁts in decreas-
ing patients’ symptoms or improving function among
those who do survive. In addition, use of PRO instru-
ments allows patients a voice in both development of
clinical trial end points and measurement of beneﬁts of
therapeutic interventions. Finally, when investigators
employ PRO instruments, they can provide informa-
tion to patients that will enable them to assess the
value of new therapies and to understand their treat-
ment regimens.
In an age that is moving toward “individualized
medicine” it seems logical that health-related needs as
expressed by patients logically play a central role in the
design and analysis of trial results. A successful
medical product development program that employs a
PRO instrument requires careful planning and clear
objectives. Using the guidance as a basis for discussion
between sponsors and FDA at all stages of product
and PRO development offers the greatest prospect of
success in demonstrating beneﬁt from use of new
therapies that will protect and promote the public
health.
Novel End Points and Methods
PROs are routinely used in many therapeutic areas as
clinical end points. Inevitably, of course, new PRO
concepts and assessments will be proposed as the ﬁeld
of PRO research addresses assessment needs for new
products. The FDA welcomes new approaches and
ways of documenting treatment beneﬁt, but the
Agency will require time to understand the value,
proper use, and interpretation of these innovations,
depending on the speed of accumulating the evidence
base and experience with innovative methods.
An important case in point is the developing use of
new electronic methods for capturing and transmitting
PRO data to the FDA, such as electronic diaries
or momentary assessments, commonly referred to as
e-PROs. Devices for collecting and transmitting data
electronically offer many new ways to capture PRO
assessments that have not been used in previous clini-
cal trials with paper and pencil administration of
PROs using retrospective recall periods. Sponsors,
vendors for electronic monitoring and data capture,
and the FDA all face a learning period to establishing
conﬁdence that the data provided are valid and reliable
in a manner that is consistent with federal regulations
and statutes, as well as with good clinical trials proce-
dures. FDA welcomes the advancements promised by
e-PRO assessment in trials but encourages sponsors to
work closely with the Agency to ensure that the instru-
ment and its implementation meet all the relevant
requirements to support product claims.
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Food and Drug Administration also is open to the
use of new methods for evaluating the measurement
properties of PRO instruments. Item-response
methods or methods based on modern test theory offer
new potential advantages over classical psychometric,
such as dynamic testing. Applications using unfamiliar
methods will likely require more review time so that
reviewers can understand the methodology as well as
learn to interpret the results. Sponsors are encouraged
to provide reports that include traditional measure-
ment property assessments as well as novel approaches
to make the links among methods more apparent
during FDA’s review.
The draft PRO guidance acknowledges and rein-
forces the importance of PRO measures for under-
standing the treatment beneﬁt of new therapies. It
explains conditions for PRO use within the context of
FDA regulations, and it highlights areas of research
needed to resolve outstanding issues in PRO research
for medical product development. With this guidance
in place, sponsors, clinicians, researchers, and FDA
will have a common understanding of FDA’s concerns
and a better opportunity to plan for successful clinical
development programs so that safe and effective
medical products can be made available to the US
public as quickly as possible.
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